Cited 2 times in
Management of Clevudine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 이정일 | - |
dc.date.accessioned | 2018-07-20T08:12:32Z | - |
dc.date.available | 2018-07-20T08:12:32Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 1976-2283 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/160965 | - |
dc.description.abstract | Background/Aims: Data are lacking regarding the management of chronic hepatitis B (CHB) with resistance to clevudine (CLV). This study evaluated the efficacy of different rescue therapies for CLV-resistant CHB. Methods: Patients with CLV-resistant CHB were enrolled in the cohort, and all patients developed virologic breakthrough during CLV therapy and had confirmed-genotypic resistance to CLV (rtM204I mutation) before enrollment. Results: Of the 107 patients, 12 received adefovir (ADV), 21 received a CLV plus ADV combination (CLV+ADV), 34 received a lamivudine plus ADV combination (LAM+ADV), and 40 received entecavir (ETV) therapy for 48 weeks. The CLV+ADV group had the lowest hepatitis B virus (HBV) DNA level (p<0.0001) and showed the greatest reduction of HBV DNA levels from baseline compared to all other groups (p=0.004) at week 48. HBV DNA was undetectable (<70 IU/mL) in 0%, 57.1%, 21.2%, and 27.5% (p=0.003) of the patients in each group, respectively, at week 48. At the end of the study, the mean alanine transaminase (ALT) level, rate of ALT normalization, and rate of hepatitis B envelope antigen loss or seroconversion did not differ between groups. Conclusions: CLV+ADV combination therapy in patients with CLV-resistant CHB more effectively suppresses HBV replication than ETV, ADV, or LAM+ADV therapy. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Editorial Office of Gut and Liver | - |
dc.relation.isPartOf | GUT AND LIVER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adenine/analogs & derivatives* | - |
dc.subject.MESH | Adenine/therapeutic use | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antiviral Agents/therapeutic use* | - |
dc.subject.MESH | Arabinofuranosyluracil/analogs & derivatives* | - |
dc.subject.MESH | Arabinofuranosyluracil/therapeutic use | - |
dc.subject.MESH | Cohort Studies | - |
dc.subject.MESH | DNA, Viral/blood | - |
dc.subject.MESH | Disease Management | - |
dc.subject.MESH | Drug Resistance, Viral/genetics | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Genotype | - |
dc.subject.MESH | Guanine/analogs & derivatives* | - |
dc.subject.MESH | Guanine/therapeutic use | - |
dc.subject.MESH | Hepatitis B virus/genetics | - |
dc.subject.MESH | Hepatitis B, Chronic/blood | - |
dc.subject.MESH | Hepatitis B, Chronic/drug therapy* | - |
dc.subject.MESH | Hepatitis B, Chronic/virology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lamivudine/therapeutic use* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Organophosphonates/therapeutic use* | - |
dc.subject.MESH | Viral Load | - |
dc.title | Management of Clevudine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Eun Young Cho | - |
dc.contributor.googleauthor | Hyung Joon Yim | - |
dc.contributor.googleauthor | Young Kul Jung | - |
dc.contributor.googleauthor | Sang Jun Suh | - |
dc.contributor.googleauthor | Yeon Seok Seo | - |
dc.contributor.googleauthor | Ji Hoon Kim | - |
dc.contributor.googleauthor | Hong Soo Kim | - |
dc.contributor.googleauthor | Sae Hwan Lee | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | Jeong Il Lee | - |
dc.contributor.googleauthor | Sook-Hyang Jeong | - |
dc.contributor.googleauthor | Jin-Wook Kim | - |
dc.contributor.googleauthor | Jin-Woo Lee | - |
dc.contributor.googleauthor | In Hee Kim | - |
dc.contributor.googleauthor | Hyoung Su Kim | - |
dc.contributor.googleauthor | Sang Jong Park | - |
dc.contributor.googleauthor | Jeong Mi Lee | - |
dc.contributor.googleauthor | Seong Gyu Hwang | - |
dc.contributor.googleauthor | on behalf of Antiviral Resistance Study Group | - |
dc.identifier.doi | 10.5009/gnl15597 | - |
dc.contributor.localId | A02226 | - |
dc.relation.journalcode | J00954 | - |
dc.identifier.eissn | 2005-1212 | - |
dc.identifier.pmid | 27538443 | - |
dc.subject.keyword | Clevudine | - |
dc.subject.keyword | Hepatitis B, chronic | - |
dc.subject.keyword | Resistance | - |
dc.subject.keyword | Therapy | - |
dc.contributor.alternativeName | Ahn, Sang Hoon | - |
dc.contributor.affiliatedAuthor | Ahn, Sang Hoon | - |
dc.citation.volume | 11 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 129 | - |
dc.citation.endPage | 135 | - |
dc.identifier.bibliographicCitation | GUT AND LIVER, Vol.11(1) : 129-135, 2017 | - |
dc.identifier.rimsid | 60859 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.